It has been announced that more drugs will be added to the Risk Sharing Agreements (RSAs) track, which will help to improve patient access and reduce uncertainties.

In December, the ‘Improvement of the Drug Pricing System to Ensure Fair-value Compensation for Innovative New Drugs and Healthcare Security’ was announced. Under this system, drugs to treat ‘Irreversible Chronic and Severe Diseases’ will be eligible for the RSAs track.

The current RSAs only applies to anticancer and orphan drugs, which treat life-threatening and severe diseases that cannot be treated with substitute drugs. In the future, the RSAs will cover drugs that are used to treat chronic and severe diseases that c